Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2017

View Archived Issues

Treatment of Clostridium difficile infection with intravenous DS-11960558 shows promise

HSV-1 seropositive mice model developed to test anti-HSV-2 vaccine

Phase IIa study finds acceptable safety with MEDI-8852 in patients with influenza A

FDA grants breakthrough therapy designation to Ansun Biopharma's DAS-181

Boston Biomedical's DSP-7888 awarded orphan status in U.S. for brain cancer

rs2516513 SNP increases bezlotoxumab treatment response in Clostridium difficile infection

Anti-ALDH2 gene therapy could discourage alcohol intake

Ovid Therapeutics's OV-101 gains new FDA orphan designation

FDA grants priority review to BLA for burosumab

First patient treated in Abide's phase I study of ABX-1431 in neuromyelitis optica

FDA issues complete response letter for BLA for biosimilar pegfilgrastim MYL-1401H

Phase III JUNIPER study of abemaciclib in NSCLC misses primary endpoint

FDA accepts NDA for ulipristal acetate to treat abnormal uterine bleeding in uterine fibroids

KalVista and Merck & Co. collaborate on KVD-001 and DME compounds

OncoSec Medical begins registration-directed trial of ImmunoPulse IL-12 plus Keytruda

AnaptysBio promising proof-of-concept data for ANB-020 in atopic dermatitis

Novel Parkinson's disease mouse model developed

Spero licenses oral carbapenem from Meiji Seika

Kaleido Biosciences enters microbiome collaboration with CoreBiome

Bristol-Myers Squibb presents compounds for treating HCV infections

GamaMabs enters licensing agreement with MedImmune

Generon reaches SPA agreement with FDA on pivotal study of F-627 in chemotherapy-induced neutropenia

Melinta Therapeutics completes phase I study of radezolid in acne

DUB inhibitors presented by Mission Therapeutics

AbbVie and Turnstone Biologics collaborate on oncolytic viral immunotherapies

Merck & Co. divulges novel Nav1.7 channel blockers

Afferent Pharmaceuticals identifies P2X2/3 receptor antagonists

Merck & Co. discloses CHRNA7 PAMs

FDA awards fast track designation to Astellas' gilteritinib

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...